Dezapelisib

Drug Profile

Dezapelisib

Alternative Names: INCB-40093; INCB040093

Latest Information Update: 15 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Incyte Corporation
  • Class Antineoplastics; Purines; Pyrimidinones; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hodgkin's disease; Non-Hodgkin's lymphoma

Most Recent Events

  • 08 May 2017 Incyte corporation terminates a phase II trial in Hodgkin's disease (Monotherapy, Combination therapy, Second-line therapy or greater, Recurrent) in USA (PO) (NCT02456675) due to the changing treatment landscape for the development of new agents in combination in Hodgkin lymphoma
  • 01 Jan 2017 Incyte corporation completes a phase-II trial in Hodgkin's disease (Monotherapy, Combination therapy, Second-line therapy or greater, Recurrent) in USA (PO) (NCT02456675)
  • 12 Dec 2016 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top